PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Center for Genome Technology and Biomolecular Engineering, Columbia University, New York, NY, 10027, USA.\', \'Department of Chemical Engineering, Columbia University, New York, NY, 10027, USA.\', \'Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.\', \'National Institute for Science and Technology for Innovation on Diseases of Neglected Population (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.\', \'Department of Chemistry, Columbia University, New York, NY, 10027, USA.\', \'Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.\', \'National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.\', \'Laboratory of Structural Biology, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.\', \'Laboratory of RNA Molecular Biology, Rockefeller University, New York, NY, 10065, USA.\', \'Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil. tmoreno@cdts.fiocruz.br.\', \'National Institute for Science and Technology for Innovation on Diseases of Neglected Population (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil. tmoreno@cdts.fiocruz.br.\', \'Center for Genome Technology and Biomolecular Engineering, Columbia University, New York, NY, 10027, USA. dj222@columbia.edu.\', \'Department of Chemical Engineering, Columbia University, New York, NY, 10027, USA. dj222@columbia.edu.\', \'Department of Molecular Pharmacology and Therapeutics, Columbia University, New York, NY, 10032, USA. dj222@columbia.edu.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s42003-022-03101-9
?:hasPublicationType
?:journal
  • Communications biology
is ?:pmid of
?:pmid
?:pmid
  • 35194144
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35194144>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35194144>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all